Cargando…
Development of a novel plaque reduction neutralisation test for hantavirus infection
In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto Oswaldo Cruz, Ministério da Saúde
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569825/ https://www.ncbi.nlm.nih.gov/pubmed/26132430 http://dx.doi.org/10.1590/0074-02760150102 |
_version_ | 1782390111831326720 |
---|---|
author | de Pádua, Michelly de Souza, William Marciel Lauretti, Flávio Figueiredo, Luiz Tadeu Moraes |
author_facet | de Pádua, Michelly de Souza, William Marciel Lauretti, Flávio Figueiredo, Luiz Tadeu Moraes |
author_sort | de Pádua, Michelly |
collection | PubMed |
description | In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for detecting antibodies to Brazilian hantavirus. Using PRNT, plaque detection was enhanced by adding 0.6% of dimethyl sulfoxide into the overlay culture medium of the infected cells. This procedure facilitated clear visualisation of small plaques under the microscope and provided for easy and accurate plaque counting. The sera from 37 HCPS patients from the city of Ribeirão Preto, Brazil was evaluated for the Rio Mamoré virus (RIOMV) using PRNT. Six samples exhibited neutralising antibodies; these antibodies exhibited a low titre. The low level of seropositive samples may be due to fewer cross-reactions between two different hantavirus species; the patients were likely infected by Araraquara virus (a virus that has not been isolated) and RIOMV was used for the test. This assay offers a new approach to evaluating and measuring neutralising antibodies produced during hantavirus infections and it can be adapted to other hantaviruses, including viruses that will be isolated in the future. |
format | Online Article Text |
id | pubmed-4569825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Instituto Oswaldo Cruz, Ministério da Saúde |
record_format | MEDLINE/PubMed |
spelling | pubmed-45698252015-09-15 Development of a novel plaque reduction neutralisation test for hantavirus infection de Pádua, Michelly de Souza, William Marciel Lauretti, Flávio Figueiredo, Luiz Tadeu Moraes Mem Inst Oswaldo Cruz Articles In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for detecting antibodies to Brazilian hantavirus. Using PRNT, plaque detection was enhanced by adding 0.6% of dimethyl sulfoxide into the overlay culture medium of the infected cells. This procedure facilitated clear visualisation of small plaques under the microscope and provided for easy and accurate plaque counting. The sera from 37 HCPS patients from the city of Ribeirão Preto, Brazil was evaluated for the Rio Mamoré virus (RIOMV) using PRNT. Six samples exhibited neutralising antibodies; these antibodies exhibited a low titre. The low level of seropositive samples may be due to fewer cross-reactions between two different hantavirus species; the patients were likely infected by Araraquara virus (a virus that has not been isolated) and RIOMV was used for the test. This assay offers a new approach to evaluating and measuring neutralising antibodies produced during hantavirus infections and it can be adapted to other hantaviruses, including viruses that will be isolated in the future. Instituto Oswaldo Cruz, Ministério da Saúde 2015-08 /pmc/articles/PMC4569825/ /pubmed/26132430 http://dx.doi.org/10.1590/0074-02760150102 Text en http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles de Pádua, Michelly de Souza, William Marciel Lauretti, Flávio Figueiredo, Luiz Tadeu Moraes Development of a novel plaque reduction neutralisation test for hantavirus infection |
title | Development of a novel plaque reduction neutralisation test for
hantavirus infection |
title_full | Development of a novel plaque reduction neutralisation test for
hantavirus infection |
title_fullStr | Development of a novel plaque reduction neutralisation test for
hantavirus infection |
title_full_unstemmed | Development of a novel plaque reduction neutralisation test for
hantavirus infection |
title_short | Development of a novel plaque reduction neutralisation test for
hantavirus infection |
title_sort | development of a novel plaque reduction neutralisation test for
hantavirus infection |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569825/ https://www.ncbi.nlm.nih.gov/pubmed/26132430 http://dx.doi.org/10.1590/0074-02760150102 |
work_keys_str_mv | AT depaduamichelly developmentofanovelplaquereductionneutralisationtestforhantavirusinfection AT desouzawilliammarciel developmentofanovelplaquereductionneutralisationtestforhantavirusinfection AT laurettiflavio developmentofanovelplaquereductionneutralisationtestforhantavirusinfection AT figueiredoluiztadeumoraes developmentofanovelplaquereductionneutralisationtestforhantavirusinfection |